Streamlining UPMC Health Plan Skyrizi Prior Authorization
Navigating the UPMC Health Plan Skyrizi prior authorization process can be complex, impacting patient access to this critical IL-23 inhibitor. Klivira streamlines the ePA workflow, enhancing efficiency and reducing administrative burden.
For revenue cycle directors and prior authorization coordinators, delays in securing approval for high-cost specialty medications like Skyrizi directly affect patient care timelines and clinic revenue. Understanding the specific requirements for UPMC Health Plan members is crucial to minimize rejections and accelerate therapy initiation for indications such as plaque psoriasis, psoriatic arthritis, and Crohn's disease.
UPMC Health Plan's Approach to Specialty Medications
UPMC Health Plan, like other large payers, employs specific strategies for managing high-cost specialty drugs such as Skyrizi (risankizumab). These strategies typically involve a designated formulary, a preferred PBM partner, and robust utilization management protocols to ensure appropriate use and cost containment. IL-23 inhibitors like Skyrizi fall under this stringent review framework.
Skyrizi Formulary Placement and Coverage Considerations
Skyrizi, an IL-23 inhibitor indicated for conditions including plaque psoriasis, psoriatic arthritis, and Crohn's disease, is generally placed on higher formulary tiers (e.g., Tier 4 or 5) due to its specialty drug classification. Providers must consult the most current UPMC Health Plan formulary to confirm its precise tiering and any associated coverage restrictions, which invariably include a prior authorization requirement.
Common Prior Authorization Hurdles for Skyrizi with UPMC Health Plan
- Documentation of failure or contraindication to specific conventional systemic therapies (step therapy).
- Quantity limits (QL) based on the approved indication and dosing guidelines.
- Specific diagnostic criteria and severity assessments (e.g., PASI score for psoriasis, confirmed endoscopic evidence for Crohn's).
- Clinical notes detailing the patient's treatment history and rationale for Skyrizi.
- Confirmation of specific laboratory results or biomarker presence, if applicable.
UPMC Health Plan's PBM and Specialty Pharmacy Routing for Skyrizi
UPMC Health Plan often manages its pharmacy benefits, including specialty medications like Skyrizi, through its own integrated PBM services or a designated partner. As a specialty drug, risankizumab will typically be dispensed exclusively through a UPMC-approved specialty pharmacy. This necessitates precise coordination during the prior authorization process to ensure seamless approval-to-dispensing workflow.
Leveraging Technology for UPMC Health Plan Skyrizi Prior Authorizations
Klivira integrates with EMR systems and payer portals to automate the submission of electronic prior authorizations (ePA) for medications like Skyrizi. By facilitating the secure exchange of X12 278 transactions and supporting NCPDP SCRIPT standards, our platform reduces the manual burden on staff, minimizes data entry errors, and accelerates the approval process for UPMC Health Plan members.
Ensuring Compliance and Data Exchange for Specialty Drug PAs
The electronic exchange of protected health information (PHI) for prior authorizations, especially for specialty drugs, demands strict adherence to HIPAA guidelines. Klivira ensures secure, auditable data flows, leveraging industry standards like SMART on FHIR and Da Vinci PAS where applicable, to maintain compliance while optimizing communication between providers, UPMC Health Plan, and their PBM for risankizumab approvals.
Frequently asked questions
What are the typical step-therapy requirements for Skyrizi under UPMC Health Plan?
UPMC Health Plan generally requires documentation of failure or contraindication to less costly, first-line therapies before approving Skyrizi for conditions like plaque psoriasis or psoriatic arthritis. Specific criteria vary by indication and the current formulary version, necessitating a review of UPMC's most recent clinical guidelines.
Does UPMC Health Plan utilize a specific PBM for Skyrizi prior authorizations?
UPMC Health Plan manages its pharmacy benefits, including specialty drugs like Skyrizi, often through its own integrated PBM services or a designated partner. It is essential for providers to confirm the specific PBM and specialty pharmacy network for current members to ensure accurate submission and routing of PA requests.
How can we confirm the current formulary tier for Skyrizi with UPMC Health Plan?
The most accurate way to confirm Skyrizi's formulary tier and specific prior authorization requirements is to consult the latest UPMC Health Plan formulary document. This is typically available on their secure provider portal or can be obtained by contacting their provider services directly.
What data standards does Klivira use to integrate with UPMC Health Plan for Skyrizi PAs?
Klivira supports industry standards such as X12 278 for electronic prior authorization, NCPDP SCRIPT for e-prescribing with PA attachments, and FHIR-based exchanges where available. These standards facilitate secure, efficient communication between providers, UPMC Health Plan, and their PBMs, streamlining the Skyrizi PA process.
Can Klivira automate the collection of clinical documentation required for UPMC Health Plan Skyrizi PAs?
Yes, Klivira integrates directly with EMR systems to extract relevant clinical data for Skyrizi prior authorization submissions. This minimizes manual chart review and ensures all necessary information, such as diagnosis codes, treatment history, and specific lab results, is accurately included in the ePA request to UPMC Health Plan.
Related coverage
Ready to automate prior auth for this plan?
See how Klivira automates prior authorizations for your team.
Request a demo